Carpmaels maintains ranking as a leading firm in patent filing and litigation
Carpmaels and Ransford has maintained its position with 13 partners again being recognised as recommended individuals in the 2025 JUVE Patent UK rankings. The firm was also named as a leading firm in pharma and biotechnology, medical technology, chemistry, digital communication and computer technology, and electronics, whilst also retaining a 3 star ranking in the litigation category.
The recommended individuals in the 2025 edition are: Jennifer Antcliff, Ian Kirby, Agathe Michel-de Cazotte, Harvey Adams, John Brunner, Stephen Duffield, Hugh Goodfellow, Cameron Marshall, Emily Nikolic, Edward Oates, Gary Small, James Warner, and Daniel Wise.
JUVE had the following comments about the firm;
The firm coordinates numerous pan-European disputes for pharmaceutical originators such as Novartis, Johnson & Johnson, Sanofi, and Takeda. This stems from the firm’s robust patent prosecution work in this sector. Through intensive EPO opposition work by renowned patent attorneys such as Stephen Duffield, Cameron Marshall, Edward Oates, and Daniel Wise, the firm frequently finds itself at the heart of major European life sciences disputes.
The legal team led by Jennifer Antcliff and Agathe Michel-de Cazotte demonstrates how deeply Carpmaels has embedded itself in the life sciences industry. In this segment, Carpmaels now competes directly with London’s leading practices, including Bristows, Powell Gilbert and Bird & Bird.
Regarding the UPC, JUVE remarked:
The UK firm is one of few British outfits to establish itself quickly at the new court. It appeared in some of the UPC’s first life sciences disputes, including the high-profile battle over cholesterol-lowering drug Praluent. Carpmaels had previously advised Sanofi and Regeneron in national and EPO proceedings alongside Hoffmann Eitle. The mixed firm also made an early appearance at the Düsseldorf local division for Curio Bioscience against 10x Genomics.
Read the rankings in full.
